Balancing risks and benefits of therapy for patients with favorable-risk limited-stage hodgkin lymphoma: The role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy alone

Hematology/Oncology Clinics of North America

Volumn 28, Issue 1, 2014, Pages 49-63

  Hay, Annette E ^a   Meyer, Ralph M ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Chemotherapy; Combined modality therapy; Hodgkin lymphoma; Radiation therapy; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EVENT FREE SURVIVAL; FOLLOW UP; HODGKIN DISEASE; HUMAN; LONG TERM SURVIVAL; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SECOND CANCER;

CHEMOTHERAPY; COMBINED MODALITY THERAPY; HODGKIN LYMPHOMA; RADIATION THERAPY; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DECISION MAKING; DOXORUBICIN; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME; VINBLASTINE;

EID: 84888793159     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2013.10.001     Document Type: Review

References (52)

1. Gall E.A. The surgical treatment of malignant lymphoma. Ann Surg 1943, 118(6):1064-1070.
2. Pack G.T., Molander D.W. The surgical treatment of Hodgkin's disease. Cancer Res 1966, 26(6 Part 1):1254-1263.
3. Gilbert R., Babaianta L. Notre methode de roentgentherapie da la lymphogranulomatose (Hodgkin): resultats eloignes. Acta Radiol 1931, 12(6):523-529. [in French].
4. Peters M.V. Astudy of survivals in Hodgkin's disease treated radiologically. Am J Roentgenol Radium Ther 1950, 63:299-311.
5. Kaplan H.S. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 1962, 78:553-561.
6. Carde P., Burgers J.M., Henry-Amar M., et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. JClin Oncol 1988, 6(2):239-252.
7. Tubiana M., Henry-Amar M., Hayat M., et al. The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy. Int J Radiat Oncol Biol Phys 1984, 10(2):197-210.
8. Dameshek W., Weisfuse L., Stein T. Nitrogen mustard in Hodgkin's disease: analysis of fifty consecutive cases. Blood 1949, 4(4):338-379.
9. Devita J.R., Serpick A.A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970, 73(6):881-895.
10. Engert A., Franklin J., Eich H.T., et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 Trial. JClin Oncol 2007, 25(23):3495-3502.
11. Ferme C., Eghbali H., Meerwaldt J.H., et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. NEngl J Med 2007, 357(19):1916-1927.
12. Press O.W., LeBlanc M., Lichter A.S., et al. Phase III randomized Intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. JClin Oncol 2001, 19(22):4238-4244.
13. Henry-Amar M., Aeppli D.M., Anderson J. Long term survival and study of causes of death. Treatment strategy in Hodgkin's disease 1990, 381-418. John Libbey, London. R. Somers, M. Henry-Amar, J.K. Meerwaldt, P. Carde (Eds.).
14. Carde P., Hagenbeek A., Hayat M., et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. JClin Oncol 1993, 11(11):2258-2272.
15. Engert A., Plutschow A., Eich H.T., et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. NEngl J Med 2010, 363(7):640-652.
16. Meyer R.M., Gospodarowicz M.K., Connors J.M., et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. NEngl J Med 2011, 366(5):399-408.
17. Radford J., Barrington S., Counsell N., et al. Involved field radiotherapy versus no further treatment in patients with clinical stages IA and IIA Hodgkin lymphoma and a 'negative' PET scan after 3 cycles ABVD. Results of the UK NCRI RAPID Trial. ASH Annual Meeting Abstracts 2012, 120(21):547.
18. Andre M.P., Reman O., Federico M., et al. Interim analysis of the randomized EORTC/LYSA/FIL Intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma. ASH Annual Meeting Abstracts 2012, 120(21):549.
19. Meyer R.M., Hoppe R.T. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Blood 2012, 120(23):4488-4495.
20. NCCN clinical practice guidelines in oncology: Hodgkin lymphoma. National Comprehensive Cancer Network. 2013;(Version 2). Available at:. Accessed September 8, 2013. http://www.nccn.org/.
21. Eichenauer D.A., Engert A., Dreyling M., On behalf of the ESMO Guidelines Working Group Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(Suppl 6):vi55-vi58.
22. Brusamolino E., Bacigalupo A., Barosi G., et al. Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica 2009, 94(4):550-565.
23. Das P, Ng A, Constine LS, etal. ACR Appropriateness criteria; Hodgkin's lymphoma-favorable prognosis stage I and II. American College of Radiology, 2008; Available at:. Accessed September 8, 2013. http://www.guideline.gov/content.aspx?id=32633%26search=hodgkin+lymphoma.
24. Meyer R.M., Gospodarowicz M.K., Connors J.M., et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. JClin Oncol 2005, 23(21):4634-4642.
25. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. JClin Oncol 2007, 25(5):579-586.
26. Hay A.E., Klimm B., Chen B.E., et al. An individual patient-data comparison of combined-modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 2013, [Epub ahead of print].
27. Wu L., Cook R.J. Misspecification of Cox regression models with composite endpoints. Stat Med 2012, 31(28):3545-3562.
28. Pfirrmann M., Hochhaus A., Lauseker M., et al. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia 2011, 25(9):1433-1438.
29. Freemantle N., Calvert M., Wood J., et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA 2003, 289(19):2554-2559.
30. Meyer RM. Contrasting explanatory and pragmatic randomized controlled trialsin oncology. American Society Clinical Oncology Annual Meeting Book. Chicago, June 3-7, 2011. p. 31.
31. Hodgson D.C. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011, 2011(1):323-329.
32. Dores G.M., Metayer C., Curtis R.E., et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. JClin Oncol 2002, 20(16):3484-3494.
33. Engert A., Schiller P., Josting A., et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 Trial of the German Hodgkin's Lymphoma Study Group. JClin Oncol 2003, 21(19):3601-3608.
34. Sasse S., Klimm B., Goergen H., et al. Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann Oncol 2012, 23(11):2953-2959.
35. Hodgson D.C., Gilbert E.S., Dores G.M., et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. JClin Oncol 2007, 25(12):1489-1497.
36. Campbell B.A., Voss N., Pickles T., et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. JClin Oncol 2008, 26(32):5170-5174.
37. Specht L, Yahalom J, Illidge T, etal. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys, in press.
38. Pavone V., Ricardi U., Luminari S., et al. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Ann Oncol 2008, 19(4):763-768.
39. Noordijk E.M., Carde P., Dupouy N., et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 Randomized Controlled Trials. JClin Oncol 2006, 24(19):3128-3135.
40. Herbst C., Rehan F., Skoetz N., et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011, (2). CD007110.
41. Meyer R.M. Selected management issues of patients with Hodgkin lymphoma. Evidence-based hematology 2008, 365-371. Wiley-Blackwell, Chichester, West Sussex, UK. 1st edition. M.A. Crowther, J. Ginsberg, H.J. Schunemann (Eds.).
42. Straus D.J., Portlock C.S., Qin J., et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004, 104(12):3483-3489.
43. Laskar S., Gupta T., Vimal S., et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need?. JClin Oncol 2004, 22(1):62-68.
44. Wolden S.L., Chen L., Kelly K.M., et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma: a report from the Children's Oncology Group. JClin Oncol 2012, 30(26):3174-3180.
45. Eich H.T., Diehl V., Goergen H., et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 Trial. JClin Oncol 2010, 28(27):4199-4206.
46. Meyer R.M. EBV DNA: a Hodgkin lymphoma biomarker?. Blood 2013, 121(18):3541-3542.
47. Knecht H., Kongruttanachok N., Sawan B., et al. Three-dimensional telomere signatures of Hodgkin- and Reed-Sternberg cells at diagnosis identify patients with poor response to conventional chemotherapy. Transl Oncol 2012, 5(4):269-277.
48. Steidl C., Diepstra A., Lee T., et al. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood 2012, 120(17):3530-3540.
49. Kanakry J.A., Li H., Gellert L.L., et al. Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American co-operative group trial. Blood 2013, 121(18):3547-3553.
50. Hoppe B.S., Flampouri S., Su Z., et al. Effective Dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012, 84(2):449-455.
51. Fiandra C.F., Filippi A.R., Catuzzo P., et al. Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 2012, 7:186.
52. Younes A., Gopal A.K., Smith S.E., et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. JClin Oncol 2012, 30(18):2183-2189.